Ipamorelin: what this GHRP peptide is
A five-amino-acid synthetic peptide that nudges the pituitary to release the body’s own growth hormone — without the side-effect baggage of older GHRPs.
TL;DR
- Ipamorelin is a five-amino-acid synthetic peptide in the growth-hormone-releasing peptide (GHRP) family.
- It signals the pituitary gland to release the body’s own growth hormone, working at the ghrelin receptor rather than the GHRH receptor.
- In published research, ipamorelin is described as more selective than older GHRPs, with less effect on cortisol and prolactin.
What it is
Ipamorelin is a synthetic peptide built from five amino acids. It belongs to a family called growth-hormone-releasing peptides, or GHRPs (in plain English: small molecules that signal the pituitary to release growth hormone). Picture the pituitary as a thermostat. Ipamorelin is a key that opens one specific door on that thermostat (Raun et al., European Journal of Endocrinology, 1998).
The “selective” label matters. Older GHRPs sometimes also nudged cortisol and prolactin upward. Ipamorelin was designed to leave those alone.
How it works
The body has its own built-in signal that tells the pituitary, “release some growth hormone.” That signal is a hormone called ghrelin. Ipamorelin imitates ghrelin at the ghrelin receptor — a lock on the surface of pituitary cells. When ipamorelin fits the lock, the cell releases a pulse of growth hormone, much like the pulse the body itself sends overnight (Sigalos and Pastuszak, Sexual Medicine Reviews, 2018).
Because it works through this specific door, ipamorelin produces a clean growth-hormone pulse rather than a broad hormonal nudge.
Who asks about it
People usually arrive at ipamorelin through one of two doors. Some are reading about longevity science and want a more selective option. Others have heard about the CJC-1295 plus ipamorelin combination and want to know what each piece does. The question is the same: how is this different from just taking growth hormone, and why is it called a “cleaner” choice?
What the research says
The published research on ipamorelin is mostly small studies and pharmacology work. Reviews describe a more selective growth-hormone release pattern compared with older GHRPs, with less effect on cortisol and prolactin (Sigalos and Pastuszak, Sexual Medicine Reviews, 2018). Ipamorelin has also been studied in postoperative recovery contexts. Long-term outcome trials in healthy aging adults are limited.
What to know before considering it
Ipamorelin is a prescription compound that requires evaluation by a licensed clinician. Side effects in published studies have been generally mild. Anyone considering ipamorelin should review baseline IGF-1 levels and other endocrine markers with their physician before starting and during therapy.
The Halftime POV
Ipamorelin is interesting because it shows what a careful design can do. The first generation of GHRPs worked, but they were noisy. Ipamorelin trades a little raw power for cleanliness. That is the kind of trade-off worth understanding before any conversation about whether it belongs in a protocol.
Related reading:
- Ipamorelin: the selective clean GH peptide
- CJC-1295 plus ipamorelin: why they are often combined
- Sermorelin explained
FAQ
Q: What is ipamorelin? A: Ipamorelin is a five-amino-acid synthetic peptide in the growth-hormone-releasing peptide family. It signals the pituitary gland to release the body’s own growth hormone. It is one of the more selective GHRPs studied in the published literature.
Q: Is ipamorelin the same as sermorelin? A: No. Sermorelin and ipamorelin both push the body to release more of its own growth hormone, but they use different doors. Sermorelin works at the GHRH receptor. Ipamorelin works at the ghrelin receptor. Clinicians sometimes pair them for that reason.
Q: Is ipamorelin available at compounding pharmacies? A: Ipamorelin is one of the peptides included in the FDA’s spring 2026 reclassification update that returned several compounds to Category 1 status. Whether a 503A pharmacy can compound it depends on state regulations and the pharmacy’s own quality standards. Always ask the prescribing clinician.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 2018.
